<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01359046</url>
  </required_header>
  <id_info>
    <org_study_id>10-007421</org_study_id>
    <nct_id>NCT01359046</nct_id>
  </id_info>
  <brief_title>Silver-impregnated Suprapubic Catheters (SPC) in Urogynecology</brief_title>
  <official_title>Randomized Control Trial of Silver-alloy Impregnated Suprapubic Catheters in Urogynecology Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare urinary tract infection rates among women undergoing
      urogynecological procedures with a silver-alloy suprapubic catheter compared to the standard
      suprapubic catheter.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Urinary catheters are used routinely in the postoperative care of urogynecology patients
      after surgery involving the genitourinary tract. However, Urinary tract infections(UTI)
      associated with indwelling catheter is the second leading cause of nosocomial infections. 20%
      of hospital acquired bacteremia arise from UTI with an associated mortality of 10%.

      There are many different types of catheters available for use. Standard indwelling catheters
      are made from a variety of materials including polyvinyl chlorine, plastic, plain latex,
      polytetrafluoroethylene, silicone elastomer, pure silicone hydrogel and polymer hydromer.
      Specialized catheters have been developed with the aim of reducing infection. Strategies
      generally involved coating the inner, outer or both surfaces of the catheter with
      antimicrobial materials. These materials can be antibiotic or antiseptic with the most common
      antiseptic material used being silver. Silver ions are bactericidal, are used safely when
      applied topically to humans and used in controlling infections.

      Previous studies comparing UTI rates in transurethral catheters have reported a significant
      reduction of UTI rate in silver-alloy catheters with a range of 5-12% compared to standard
      catheters with a range of 7-50%. There are no studies comparing the UTI rate in silver-alloy
      supra-pubic catheters to standard supra-pubic catheters. The investigators hypothesize that
      this study will show a statistically significant decrease in UTI rate among the individuals
      with a silver-alloy suprapubic catheter compared to the standard silver-alloy catheter.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">March 9, 2018</completion_date>
  <primary_completion_date type="Actual">March 2, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary Tract Infection Rate</measure>
    <time_frame>within 6 weeks post surgery</time_frame>
    <description>Number of subjects diagnosed with a urinary tract infection (UTI) within 6 weeks of surgery. A UTI is defined as any symptoms requiring antibiotic treatment, a urine culture with &gt;10^5 cfu/mL, or a urine culture with &gt;10^3 cfu/mL and evidence of pyuria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Risk of Urinary Tract Infections in Diabetics</measure>
    <time_frame>within 6 weeks post surgery</time_frame>
    <description>Number of diabetic subjects diagnosed with a urinary tract infection within 6 weeks post surgery.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">288</enrollment>
  <condition>Infection Associated With Catheter</condition>
  <condition>Urinary Tract Infection</condition>
  <arm_group>
    <arm_group_label>silver SPC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to receive silver-impregnated SPC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard SPC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subjects randomized to receive standard SPC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>silver SPC</intervention_name>
    <description>subject randomized to receive silver alloy impregnated catheter</description>
    <arm_group_label>silver SPC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>standard SPC</intervention_name>
    <description>subject randomized to receive standard catheter</description>
    <arm_group_label>standard SPC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients requiring intra-operative placement of suprapubic catheters as part of
             routine post-operative care for repair of vaginal anterior compartment prolapse i.e.
             patients undergoing anterior colporrhaphy, Burch colposuspension, with or without
             mid-urethral sling

        Exclusion Criteria:

          -  Known UTI at time of surgery

          -  Unable to provide informed consent

          -  Use of chronic intermittent self-catheterization pre-operatively

          -  Use of chronic prophylactic antibiotics

          -  Use of antibiotics for any indication other than UTI during peri-operative and 6-week
             post-operative period

          -  Presence of fistula involving urogenital tract

          -  Use of chronic steroids or immunosuppressant

          -  Immunocompromised patient
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Gebhart, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>May 20, 2011</study_first_submitted>
  <study_first_submitted_qc>May 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2011</study_first_posted>
  <results_first_submitted>April 4, 2019</results_first_submitted>
  <results_first_submitted_qc>April 4, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 26, 2019</results_first_posted>
  <last_update_submitted>April 25, 2019</last_update_submitted>
  <last_update_submitted_qc>April 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>John B. Gebhart</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>CAUTI</keyword>
  <keyword>UTI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Catheter-Related Infections</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 25, 2011</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT01359046/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Silver SPC</title>
          <description>Subjects randomized to receive silver-impregnated SPC.
silver SPC: subject randomized to receive silver alloy impregnated catheter</description>
        </group>
        <group group_id="P2">
          <title>Standard SPC</title>
          <description>subjects randomized to receive standard SPC.
standard SPC: subject randomized to receive standard catheter</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
                <participants group_id="P2" count="144"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="137"/>
                <participants group_id="P2" count="127"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not receive allocated intervention</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Silver SPC</title>
          <description>Subjects randomized to receive silver-impregnated SPC.
silver SPC: subject randomized to receive silver alloy impregnated catheter</description>
        </group>
        <group group_id="B2">
          <title>Standard SPC</title>
          <description>subjects randomized to receive standard SPC.
standard SPC: subject randomized to receive standard catheter</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="137"/>
            <count group_id="B2" value="127"/>
            <count group_id="B3" value="264"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.7" spread="10.5"/>
                    <measurement group_id="B2" value="66.3" spread="10.4"/>
                    <measurement group_id="B3" value="65.5" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="264"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-white</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.6" spread="5.0"/>
                    <measurement group_id="B2" value="27.8" spread="5.2"/>
                    <measurement group_id="B3" value="27.7" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Urinary Tract Infection Rate</title>
        <description>Number of subjects diagnosed with a urinary tract infection (UTI) within 6 weeks of surgery. A UTI is defined as any symptoms requiring antibiotic treatment, a urine culture with &gt;10^5 cfu/mL, or a urine culture with &gt;10^3 cfu/mL and evidence of pyuria.</description>
        <time_frame>within 6 weeks post surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Silver SPC</title>
            <description>Subjects randomized to receive silver-impregnated SPC.
silver SPC: subject randomized to receive silver alloy impregnated catheter</description>
          </group>
          <group group_id="O2">
            <title>Standard SPC</title>
            <description>subjects randomized to receive standard SPC.
standard SPC: subject randomized to receive standard catheter</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Tract Infection Rate</title>
          <description>Number of subjects diagnosed with a urinary tract infection (UTI) within 6 weeks of surgery. A UTI is defined as any symptoms requiring antibiotic treatment, a urine culture with &gt;10^5 cfu/mL, or a urine culture with &gt;10^3 cfu/mL and evidence of pyuria.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.30</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Risk of Urinary Tract Infections in Diabetics</title>
        <description>Number of diabetic subjects diagnosed with a urinary tract infection within 6 weeks post surgery.</description>
        <time_frame>within 6 weeks post surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Silver SPC</title>
            <description>Subjects randomized to receive silver-impregnated SPC.
silver SPC: subject randomized to receive silver alloy impregnated catheter</description>
          </group>
          <group group_id="O2">
            <title>Standard SPC</title>
            <description>subjects randomized to receive standard SPC.
standard SPC: subject randomized to receive standard catheter</description>
          </group>
        </group_list>
        <measure>
          <title>Risk of Urinary Tract Infections in Diabetics</title>
          <description>Number of diabetic subjects diagnosed with a urinary tract infection within 6 weeks post surgery.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.68</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were captured and reported from enrollment to the 6 week post-operative period, which is the end of study treatment follow-up.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Silver SPC</title>
          <description>Subjects randomized to receive silver-impregnated SPC.
silver SPC: subject randomized to receive silver alloy impregnated catheter</description>
        </group>
        <group group_id="E2">
          <title>Standard SPC</title>
          <description>subjects randomized to receive standard SPC.
standard SPC: subject randomized to receive standard catheter</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Ureteral stent placement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Hernaturia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Reoperation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. John Gebhart</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-266-7711</phone>
      <email>gebhart.john@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

